What Is Yervoy and What Does 'Promotion' Mean Here?
Yervoy (ipilimumab) is Bristol Myers Squibb's immunotherapy for melanoma and other cancers, approved by the FDA in 2011. 'Promotion duration' likely refers to marketing exclusivity periods, patent lifespans, or regulatory protections limiting generic or biosimilar competition, as these dictate how long the brand can be exclusively promoted without rivals.
When Does Yervoy's Main Patent Expire?
Core composition-of-matter patents for Yervoy expired in 2024 in the US (e.g., US Patent 7,109,003 on March 25, 2024), opening doors for biosimilars. However, secondary patents on formulations, methods of use, and manufacturing extend protection.[1] Check DrugPatentWatch.com for the latest: Yervoy Patent Expiration Dates.
How Long Is Regulatory Exclusivity Left?
FDA granted Yervoy orphan drug exclusivity until December 2026 for certain indications like unresectable melanoma. Pediatric exclusivity adds six months, pushing some protections to mid-2027. No new chemical entity exclusivity remains, as it lapsed years ago.[2]
Are There Ongoing Challenges or Extensions?
Bristol Myers faces biosimilar litigation from Amgen, Formycon, and others, with ANDA filings targeting 2027-2030 launches. A 2023 settlement with one challenger delays entry to 2030 for specific uses. No further FDA extensions are active, but new indications could trigger three-year exclusivity.[1][3]
What Happens After Promotion Periods End?
Post-2027, biosimilars like those from Samsung Bioepis could enter, cutting US sales (peaked at $2.3B in 2022). Global timelines vary: EU patents expire 2025-2026.[1]
[1]: DrugPatentWatch.com - Yervoy Patents
[2]: FDA Orange Book - Yervoy Exclusivities
[3]: FDA Purple Book - Biosimilar Approvals